Regional footprint SteinCares has a strong commercialization platform across 24 Latin American countries with a diversified portfolio of biosimilars, complex generics, and innovative products, indicating multiple entry points for new partnerships and expanded product lines with regional healthcare providers.

Strategic partnerships Ongoing licensing and distribution agreements with global biosimilar developers (e.g., Shilpa Biologicals, Lupin, Bio-Thera, CStone, Biotest) create plug-and-play collaboration opportunities for additional products and faster market access in Latin America.

Access-driven value A stated mission to improve access to cost-effective pharmaceuticals positions SteinCares as an attractive channel partner for manufacturers seeking broader regional reach, expedited approvals, and localized market support.

Compliance and trust Consistent audit success and high compliance standards with global pharmaceutical companies reduce regulatory risk for new partnerships and enable smoother co-commercialization of biosimilars and complex generics.

Growth potential Revenue size (up to $500M) and a growing partner network signal significant scale and cross-sell opportunities across product families, enabling targeted outreach to manufacturers seeking Latino markets and to healthcare providers needing expanded access and portfolio breadth.